Cyanidin-3-O-β-glucoside, a typical anthocyanin, exhibits antilipolytic effects in 3T3-L1 adipocytes during hyperglycemia: involvement of FoxO1-mediated transcription of adipose triglyceride lipase.
Elevated concentrations of circulating free fatty acids (FFAs) have been demonstrated to potentially link obesity, insulin resistance and type 2 diabetes. Inhibition of lipolysis reduces FFAs availability and improves insulin sensitivity. Anthocyanins from different plant foods were shown to improve hyperlipidemia and insulin resistance in vivo. In this study, cyanidin-3-O-β-glucoside (C3G), a typical anthocyanin was selected to examine its in vitro effects on high-glucose-induced lipolysis in cultured 3T3-L1 adipocytes. Incubation with C3G efficiently inhibited FFAs and glycerol release from the adipocytes during hyperglycemia in a dose- and time-dependent manner. C3G treatment also increased the activity of AMP-activated protein kinase, decreased the activity of glutamine:fructose 6-phosphate aminotransferase, reduced cellular UDP-N-acetylglucosamine production, thereby suppressing the hexosamine biosynthetic pathway. In addition, C3G attenuated high-glucose-promoted O-glycosylation of transcription factor FoxO1, resulting in decreased expression of adipose triglyceride lipase (ATGL). Our findings reveal a novel mechanism by which anthocyanin regulates FoxO1-mediated transcription of ATGL and thus inhibits adipocyte lipolysis, suggesting its potential therapeutic application in diabetes-associated hyperlipidemia.
Department of Food Science, Yingdong College of Bioengineering, Shaoguan University, 512005 Shaoguan, China. guohh1999@hotmail.com
Honghui
H
Guo
Jiebiao
J
Guo
Xinwei
X
Jiang
Zhen
Z
Li
Wenhua
W
Ling
D041721:3T3-L1 Cells; D000215:Acylation; D000263:Adenylate Kinase / Q000378:metabolism; D017667:Adipocytes / Q000166:cytology / Q000187:drug effects* / Q000201:enzymology; D000818:Animals; D000872:Anthocyanins / Q000494:pharmacology*; D001483:Base Sequence; D017931:DNA Primers; D004789:Enzyme Activation; D000071161:Forkhead Box Protein O1; D051858:Forkhead Transcription Factors / Q000502:physiology*; D005947:Glucose / Q000008:administration & dosage; D005960:Glucosides / Q000494:pharmacology*; D006943:Hyperglycemia / Q000378:metabolism*; D008049:Lipase / Q000235:genetics*; D008066:Lipolysis / Q000187:drug effects*; D051379:Mice; D016133:Polymerase Chain Reaction; D014158:Transcription, Genetic / Q000502:physiology
D000872:Anthocyanins; D017931:DNA Primers; D000071161:Forkhead Box Protein O1; D051858:Forkhead Transcription Factors; C467200:Foxo1 protein, mouse; D005960:Glucosides; C462279:cyanidin-3-O-beta-glucopyranoside; D000263:Adenylate Kinase; D008049:Lipase; D005947:Glucose